|

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS

RECRUITINGSponsored by University Hospital, Brest
Actively Recruiting
SponsorUniversity Hospital, Brest
Started2021-03-18
Est. completion2026-03-18
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted

Summary

To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy. In patients with inflammatory rheumatic disorders requiring prolonged glucocorticoid therapy, such tool could be useful to adapt first-line treatment decisions (in daily practice and in future clinical trials). The main objective of the study is to identify routine clinical, biological and DXA baseline characteristics predictive of the occurrence of clinically relevant complications of glucocorticoid therapy at 1 year, in order to propose a predictive score.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Life expectancy \> 1 year.
* Indication to initiate prolonged glucocorticoid therapy at a dosage ≥ 15 mg/day for the treatment of an inflammatory rheumatic disease.
* Initial treatment or relapse.
* Previsional treatment duration \> 3 months.

Exclusion Criteria:

* Unable to consent.
* Previous corticosteroid therapy in the last 3 months at a significant dosage (\> 5 mg per day).

Conditions7

ANCA Associated VasculitisArthritisGiant Cell ArteritisIdiopathic Inflammatory MyopathiesInflammatory RheumatismPolymyalgia RheumaticaSystemic Autoimmune Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.